Novartis
Last updated on 2013-11-22T06:47+0300.
About this
image
License:
UNKNOWN
| Key Titles and Phrases | Count | Lang | Last Seen |
|---|---|---|---|
| analyst | 100.00% | EN | 05/11/2013 |
| Names | Lang | Count |
|---|---|---|
| Novartis | EN | 19.32% |
| Novartis | FR | 19.27% |
| Novartis | PT | 7.67% |
| Novartis | ES | 7.07% |
| Novartis | DE | 6.82% |
| Novartis | AR | 6.80% |
| Novartis | IT | 6.78% |
| Novartis | ID | 6.78% |
| Novartis | HR | 6.78% |
| Novartis | NL | 6.78% |
| Pharmakonzern Novartis | DE | 3.93% |
| Pharmakonzerns Novartis | DE | 0.82% |
| Pharmariesen Novartis | DE | 0.51% |
| Novartis-Konzern | DE | 0.39% |
| NOVARTIS | FR | 0.12% |
| NOVARTIS | EN | 0.07% |
| Konzerne Novartis | DE | 0.05% |
| Novartis | SA | 0.05% |
| NOVARTIS | AR | 0.02% |
| โนวาร์ติส | TH | 0.00% |
| Novartis Pharmawerte | DE | 0.00% |
| Konzern Novartis | DE | 0.00% |
| Arzneimittelhersteller Novartis | DE | 0.00% |
| Pharmaherstellers Novartis | DE | 0.00% |
| Pharma-Konzerns Novartis | DE | 0.00% |
| 诺华 | ZH | 0.00% |
| Mutterkonzern Novartis | DE | 0.00% |
| Novartis-Konzerns | DE | 0.00% |
| ノバルティス | JA | 0.00% |
| Type | Entity Name | Count |
|---|---|---|
 | Pfizer Inc | 5.61% |
| Inc | 3.53% |
| World Health Organization | 2.91% |
 | Commission | 2.49% |
| GlaxoSmithKline | 2.28% |
| European Union | 2.18% |
| European Commission | 1.87% |
| European Medicines Agency | 1.77% |
| Laura Wood | 1.66% |
| Drug Administration | 1.45% |
| Eli Lilly | 1.35% |
| Roche Holding AG | 1.25% |
| Dietmar Hopp | 1.14% |
| Strategy | 1.14% |
| Reuters Group | 1.14% |
| Pharmaceuticals Inc | 1.14% |
| la Commission | 1.04% |
| Bristol Myers Squibb | 1.04% |
| Boehringer Ingelheim | 1.04% |
| Saudi | 0.93% |
| Market Development | 0.93% |
| GlaxoSmithKline Plc | 0.83% |
| Product Development | 0.83% |
| Lonza Group | 0.83% |
| Medicines Agency | 0.73% |
| Merck KGaA | 0.62% |
| German government | 0.62% |
| AstraZeneca PLC | 0.62% |
| American Society | 0.62% |
| Abbott Laboratories | 0.62% |
| Type | Entity Name | Score |
|---|---|---|
| GlaxoSmithKline | 0.0191 |
| Annette Nijs | 0.0154 |
| European Medicines Agency | 0.0145 |
| Laura Wood | 0.0132 |
| Eli Lilly | 0.0117 |
| Roche Holding AG | 0.0115 |
| Dietmar Hopp | 0.0109 |
| Pfizer Inc | 0.0108 |
| Pharmaceuticals Inc | 0.0103 |
| Bristol Myers Squibb | 0.0101 |
| Boehringer Ingelheim | 0.0096 |
| Market Development | 0.0093 |
| Drug Administration | 0.0086 |
| Product Development | 0.0083 |
| GlaxoSmithKline Plc | 0.008 |
| Lonza Group | 0.0077 |
| Helen Zhu | 0.0073 |
| la Commission | 0.0072 |
| Strategy | 0.0068 |
| European Commission | 0.0066 |
| Merck KGaA | 0.0062 |
| AstraZeneca PLC | 0.0061 |
| Peter Hotez | 0.006 |
| Amesh Adalja | 0.006 |
| Medicines Agency | 0.0059 |
| Teva Pharmaceuticals | 0.0059 |
| Baylor College | 0.0059 |
| Zurich Insurance Group | 0.0059 |
| American Society | 0.0058 |
| Abbott Laboratories | 0.0057 |
Show/hide duplicate news articles.
Show/hide duplicate news articles.
Tools
Monday, January 24, 2022
9:40:00 AM EAT
Languages 
Select your languages
Explore Relations
Please send any comments or suggestions to 